Floatz logo

Hrs-1167

Recurrent Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the Recurrent Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Carotuximab
Tracon Pharmaceuticals Inc.
Phase 2B
METHYLPREDNISOLONE ACETATE IMPURITY E
AbbVie
Phase 2CCC
Brimonidine
AbbVie
Phase 2CCC
Ivonescimab
Akeso
Phase 2CCC
INTERFERON ALFA-2B
Leiden University Medical Center
Phase 1/2CCC

View all 17 →

Same molecule, other indications

Hrs-1167 is also rated in:

breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Her2-receptor negative breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →